STATEMENT OF PURPOSE
RS28135 / S1017
The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled
Substances Act. This bill mirrors the federal Drug Enforcement Administration (DEA) controlled substance
scheduling and descheduling decisions for 2020, including placing synthetic cannabinoids in Schedule I, an
opiate in schedule II and another substance in Schedule V as well as one technical correction in Schedule IV.
FISCAL NOTE
This legislation will have no fiscal impact to the General Fund or the Board of Pharmacy's dedicated fund. It
has no fiscal impact because adding, removing, or rescheduling products to the Controlled Substances Act does
not create any new state program and does not compel any state action.
Contact:
Nicki Chopski
Idaho Division of Occupational and Professional Licenses
(208) 334-2356
DISCLAIMER: This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent
of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative
process, including judicial review (Joint Rule 18).
Statement of Purpose / Fiscal Note Bill SOP/FN INTRODUCED: 01/19/2021, 4:52 PM


Statutes affected:
Bill Text: 37-2701, 37-2705, 37-2707, 37-2711, 37-2713